Back to News
Market Impact: 0.2
Vivos Therapeutics Exchanges $2.86 Million Of Debt For Shares; Stock Down
Source: Nasdaq
Healthcare & BiotechM&A & RestructuringCompany Fundamentals
Vivos Therapeutics entered into 12 exchange agreements with Streeterville Capital on August 31, 2026, covering $2.86 million of outstanding principal under secured promissory obligations. The transaction signals a restructuring of existing debt, though the available article text does not disclose the exchange terms, resulting securities, or balance-sheet impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
0.10
Ticker Sentiment
VVOS0.15
More News
- Here’s the ‘core economic flaw’ in the AI bull case as stock and bond trades unravel, according to a top economist
- How Pepsi fell behind in the cola wars—and then lost KFC
- 5 big analyst AI moves: ’Uniquely catalyst-rich’ months ahead for SpaceX
- Braskem creditors, shareholders near deal on $11bn debt restructuring
- Brookfield to open Qatar office as it expands Middle East operations
- Xencor reports phase 1 data for cancer drug XmAb819
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Best AI Stock Research Tools for Professional Investors
- Weekly Update: Adding Live MBO Level 3 Data - Liquidity Heatmap, OFI Charts, and More